Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | MLKL | Q8NB16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL875176 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL29870420 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL26299278 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL661478 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL661021 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL851826 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL661377 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL6555279 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL660625 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL16559904 | 1.00 | USP2 (0.52) | USP2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 145 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111589420-A | Millimeter-grade macroporous-mesoporous carbon sphere/cup [4] -double crown-6 interpenetrating composite material and preparation method and application thereof | 东华理工大学 | 2020-08-28 | — | — | CN | claimed |
| CN-110180504-A | Carbon-based asymmetric double crown supermolecule hybrid material of one kind and its preparation method and application | 东华理工大学 | 2019-08-30 | — | — | CN | claimed |
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2025-01-30 | — | — | US | disclosed |
| US-12024486-B2 | Lipocationic dendrimers and uses thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-07-02 | — | — | US | disclosed |
| US-11958854-B2 | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES, LLC (US) | 2024-04-16 | — | — | US | disclosed |
| US-20240025848-A1 | LIPOCATIONIC DENDRIMERS AND USES THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-01-25 | — | — | US | disclosed |
| US-11858884-B2 | Compositions and methods for modulating gene or gene product in cells | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-01-02 | — | — | US | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-11660303-B2 | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | KANCERA AB (SE) | 2023-05-30 | — | — | US | disclosed |
| EP-3294714-B1 | MORPHINAN DERIVATIVES FOR THE TREATMENT OF NEUROPATHIC PAIN | NEKTAR THERAPEUTICS (US) | 2023-03-15 | — | — | EP | disclosed |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | HYDRA BIOSCIENCES, LLC (US) | 2023-02-09 | — | — | US | disclosed |
| WO-2009026537-A1 | BENZYLBENZENE DERIVATIVES AND METHODS OF USE | THERACOS, INC. (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20070135351-A1 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | CONDE-KNAPE KARIN | 2007-06-14 | — | — | US | disclosed |
| WO-2005000941-A1 | NOVEL POLYMER COMPOSITIONS | DOW GLOBAL TECHNOLOGIES, INC. (US) | 2005-01-06 | — | — | WO | disclosed |
| US-20040249067-A1 | Novel polymer compositions | FOX MARTIN EDWARD (GB) | 2004-12-09 | — | — | US | disclosed |
| US-20040249119-A1 | Novel mPEG propionaldehyde precursor | FOX MARTIN EDWARD (GB) | 2004-12-09 | — | — | US | disclosed |
| EP-0349748-B1 | SUBSTITUTED N-ARYL-NITROGEN CONTAINING HETEROCYCLES | BAYER AG (DE) | 1992-11-19 | — | — | EP | disclosed |
| US-5118849-A | Arylamines intermediates | BAYER AKTIENGESELLSCHAFT (DE) | 1992-06-02 | — | — | US | disclosed |
| US-5039334-A | Herbicidal and plant growth-regulating substituted N-aryl nitrogen heterocycles | BAYER AKTIENGESELLSCHAFT (DE) | 1991-08-13 | — | — | US | disclosed |
| EP-0349748-A1 | Substituted N-aryl-nitrogen containing heterocycles | BAYER AG (DE) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135351-A1 | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof | NPY2R, NPY1R, NPY4R | USP2 2739/4885TSHR 81/4885KDM4E 3805/4885 |
| US-20240025848-A1 | LIPOCATIONIC DENDRIMERS AND USES THEREOF | LIPA, LIPC, TLR9 | USP2 3570/4885TSHR 3143/4885KDM4E 4836/4885 |
| US-12024486-B2 | Lipocationic dendrimers and uses thereof | LIPA, LIPC, TLR9 | USP2 3570/4885TSHR 3143/4885KDM4E 4836/4885 |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | USP2 4861/4885TSHR 894/4885KDM4E 4434/4885 |
| US-11958854-B2 | Substituted xanthines and methods of use thereof | TRPC5, TRPC7, TRPC4 | USP2 4322/4885TSHR 4540/4885KDM4E 3549/4885 |
| US-20230040259-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | USP2 4322/4885TSHR 4540/4885KDM4E 3549/4885 |
| US-20250034143-A1 | SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF | TRPC5, TRPC7, TRPC4 | USP2 4322/4885TSHR 4540/4885KDM4E 3549/4885 |
| US-11858884-B2 | Compositions and methods for modulating gene or gene product in cells | DGKB, DGKG, DGKA | USP2 2976/4885TSHR 4629/4885KDM4E 4699/4885 |
| US-11660303-B2 | 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity | ROR1, RORB, RORA | USP2 4095/4885TSHR 1024/4885KDM4E 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.